Abstract
Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9-12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10-20% of TNBC patients while somatic mutations occur in 3-5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors.
Citations
Aug 29, 2019·Human Cell·Peng LiQian Qian
Oct 18, 2019·Chemical Communications : Chem Comm·Wei-Tao DouXiao-Peng He
May 27, 2020·The Oncologist·Robert WesolowskiBhuvaneswari Ramaswamy
Aug 14, 2020·Frontiers of Medicine·Hongnan Mo, Binghe Xu
Apr 3, 2020·Cancers·Anna DianaMichele Orditura
Feb 9, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Juan JinXichun Hu
Jan 15, 2021·Breast Cancer : Targets and Therapy·Ibnu PurwantoSofia Mubarika Haryana
Feb 16, 2021·Frontiers in Molecular Biosciences·Zheng DanJing Jing
May 13, 2021·Technology in Cancer Research & Treatment·Fei LuWenhui Li
Jul 10, 2021·Signal Transduction and Targeted Therapy·Ruixue Huang, Ping-Kun Zhou
Aug 15, 2021·Journal for Immunotherapy of Cancer·Leisha A EmensJennifer K Litton
Aug 31, 2021·Current Breast Cancer Reports·Jodi A KagiharaJennifer R Diamond
Oct 13, 2021·Molecular Cancer Therapeutics·Jiaojiao DengMelanie Hayden Gephart
Nov 5, 2021·Frontiers in Cell and Developmental Biology·Yue LiQian He
Nov 20, 2021·Breast Cancer Research and Treatment·Ke ZuoWentao Yang
Jan 6, 2022·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Aiko SuetaYutaka Yamamoto